Mylan and Rite Aid are facing a class action that claims the companies respectively manufactured and sold generic valsartan medications despite possessing knowledge that the drugs were contaminated with probable carcinogen N-nitrosodiethylamine (NDEA).
Thirteen new cases have been filed in Pennsylvania federal court as part of a multidistrict litigation accusing numerous pharmaceutical companies of conspiring to fix the prices of generic drugs.
Mylan Pharmaceuticals, Inc. and Mylan Specialty, L.P. are facing another proposed class action – this time filed in Alabama – alleging that they charged consumers unlawfully high prices for their EpiPen products.
Seven more lawsuits have been filed this week as part of a multidistrict litigation that accuses the pharmaceutical companies of conspiring to fix generic drug prices.
Six more lawsuits have been added to a multidistrict litigation that claims various pharmaceutical companies have conspired to fix the price of generic drugs.